Access Consortium Good Manufacturing Practice (GMP) Statement

AI Summary

This regulatory summary outlines the foundational principles of Good Manufacturing Practice (GMP) as established by international authorities such as the FDA and UK MHRA. The guidance defines GMP as a critical system designed to ensure that medicinal products are consistently produced and controlled according to the quality standards necessary for their intended use and as mandated by marketing authorizations. While the provided text serves as a broad definition rather than an inspection-specific report, it establishes the regulatory framework within which all pharmaceutical manufacturers must operate. The main objectives highlight the necessity for rigorous quality control to mitigate risks inherent in any pharmaceutical production that cannot be eliminated through testing the final product alone. In practice, failure to adhere to these standards constitutes a major violation, requiring immediate corrective and preventive actions. These actions typically involve comprehensive reviews of manufacturing processes, equipment validation, and staff training protocols. This framework ensures that companies maintain transparency and reliability, ultimately protecting public health by guaranteeing the safety, identity, strength, and purity of medicinal products.